Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 96 Rectal Neoplasms 45 Colorectal Neoplasms 45 Carcinoma, Non-Small-Cell Lung 31 Esophageal Neoplasms 28 Esophageal Squamous Cell Carcinoma 24 Stomach Neoplasms 22 Lung Neoplasms 20 Pancreatic Neoplasms 19 Squamous Cell Carcinoma of Head and Neck 18 Colonic Neoplasms 18 Sarcoma 16 Neoplasms 16 Adenocarcinoma Of Esophagus 15 Ovarian Neoplasms 14 Neoplasm Metastasis 14 Head and Neck Neoplasms 14 Carcinoma, Hepatocellular 14 Prostatic Neoplasms 13 Urinary Bladder Neoplasms 12 Uterine Cervical Neoplasms 10 Inflammatory Breast Neoplasms 9 Fallopian Tube Neoplasms 9 Osteosarcoma 8 Central Nervous System Neoplasms 8 Carcinoma, Intraductal, Noninfiltrating 8 Kidney Neoplasms 7 Carcinoma, Ovarian Epithelial 7 Recurrence 6 Multiple Myeloma 6

Interventions

atezolizumab 1 alectinib 1 Vemurafenib 1 Neoadjuvant Therapy 1 Fruit 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Genomic Instability × Neoadjuvant Therapy × Clear all

NCT06294054 2024-03-06

SELECT

University Hospital, Rouen

Urinary Bladder Neoplasms, Genomic Instability

Data powered by HemOnc (CC BY 4.0) Colophon ⚡